Predicting GLP-1 Discontinuation From Pharmacy Claims
Published: | Updated:
|Articles|April 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
- Volume 4
- Issue 4 Suppl
Participating Faculty
Advertisement
Articles in this issue
over 28 years ago
Coronary Heart Disease in the United Statesover 28 years ago
Mechanisms of Acute Coronary Eventsover 28 years ago
Primary Preventionover 28 years ago
Pravastatin Event Reduction Analysisover 28 years ago
Secondary Preventionover 28 years ago
Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?over 28 years ago
Methods and Mindsets in Pharmacoeconomicsover 28 years ago
Issues and Controversies in Pharmacoeconomicsover 28 years ago
Pharmacoeconomics Perspectives: Payers, Providers, and PatientsAdvertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
3
FDA Approves First Orexin Agonist for Narcolepsy Type 1
4
A Multi-Country Needs Assessment on MCL and CLL Management
5